Truly refractory hypertension

Hypertension

Volumn 62, Issue 2, 2013, Pages 231-235

  Schroeder, Christoph ^a,c   Heusser, Karsten ^a   Brinkmann, Julia ^a   Menne, Jan ^a   Oswald, Hanno ^a   Haller, Hermann ^a   Jordan, Jens ^a   Tank, Jens ^a   Luft, Friedrich C ^b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b VANDERBILT UNIVERSITY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BISOPROLOL; CANDESARTAN; CLONIDINE; LAMOTRIGINE; MINOXIDIL; NITROPRUSSIDE SODIUM; SPIRONOLACTONE; TORASEMIDE; URAPIDIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION;

FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; MUSCLE, SKELETAL; SYMPATHETIC NERVOUS SYSTEM;

EID: 84880953192     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01240     Document Type: Article

References (22)

1. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-547.
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
3. Swales JD, Bing RF, Heagerty A, Pohl JE, Russell GI, Thurston H. Treatment of refractory hypertension. Lancet. 1982;1:894-896.
4. Ruttanaumpawan P, Nopmaneejumruslers C, Logan AG, Lazarescu A, Qian I, Bradley TD. Association between refractory hypertension and obstructive sleep apnea. J Hypertens. 2009;27:1439-1445.
5. Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19:335-341.
6. Bertog S, Schultz JC, Franke J, Hoffman I, Sievert H. Catheter-based renal denervation for refractory hypertension: a review of the literature. J Indian Med Assoc. 2012;110:292-296.
7. Naraghi R, Geiger H, Crnac J, Huk W, Fahlbusch R, Engels G, Luft FC. Posterior fossa neurovascular anomalies in essential hypertension. Lancet. 1994;344:1466-1470.
8. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558-569.
9. Schroeder C, Stabroth C, Luft FC, Jordan J. Adrenergic cardiovascular control before and after removal of stimulatory α-1 adrenoreceptor antibodies. Hypertension. 2012;59:e6-e7.
10. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254-1258.
11. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152-158.
12. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-626.
13. Luft FC, Veelken R, Becker H, Ganten D, Lang RE, Unger T. Effect of urapidil, clonidine, and prazosin on sympathetic tone in conscious rats. Hypertension. 1986;8:303-311.
14. Isaac L. Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol. 1980;(2 suppl 1):S5-S19.
15. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376:1903-1909.
16. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-1490.
17. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
18. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens. 2012;26:463-475.
19. Patel NK, Javed S, Khan S, Papouchado M, Malizia AL, Pickering AE, Paton JF. Deep brain stimulation relieves refractory hypertension. Neurology. 2011;76:405-407.
20. Jordan J, Toka HR, Heusser K, Toka O, Shannon JR, Tank J, Diedrich A, Stabroth C, Stoffels M, Naraghi R, Oelkers W, Schuster H, Schobel HP, Haller H, Luft FC. Severely impaired baroreflex-buffering in patients with monogenic hypertension and neurovascular contact. Circulation. 2000;102:2611-2618.
21. Hattenbach LO, Toka HR, Toka O, Schuster H, Luft FC. Absence of hypertensive retinopathy in a Turkish kindred with autosomal dominant hypertension and brachydactyly. Br J Ophthalmol. 1998;82:1363-1365.
22. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270-276.